Tick-borne encephalitis (TBE) is a viral brain infection that causes 10,000 to 15,000 reported cases across Europe and Asia each year. It is endemic from the Atlantic coast of France to the forests of Hokkaido, and the range has expanded northward for two decades as warmer winters let ticks survive in places they could not before. Most US travelers in central European forests have never heard of it.
That gap matters. There is no specific antiviral for TBE. Roughly a quarter of clinically apparent infections progress to a neurological phase with meningitis, encephalitis, or paralysis, and 10 to 20% of those patients have lasting cognitive or motor problems a year later. A highly effective three-dose vaccine has been licensed in Europe for decades and was approved by the FDA in 2021, but US travel clinics rarely stock it. TBE sits inside the broader outbreak-aware travel guide, and prevention overlaps closely with the Lyme disease tick prevention guide since both diseases ride on the same tick genus.
Key Takeaways
- WHO and ECDC together report 10,000 to 15,000 TBE cases per year across Europe and Asia. Austria, Czechia, Germany, the Baltics, and Russia carry the heaviest burden; case counts are rising in Sweden, Finland, the Netherlands, and the UK.
- TBEV has three subtypes: European (mortality 1 to 2%), Siberian (2 to 3%), and Far Eastern (up to 20% with higher long-term disability).
- Vector ticks are I. ricinus across Europe and I. persulcatus in eastern Europe and Asia. The same Ixodes genus transmits Lyme, so one bite can pass on multiple pathogens.
- TICOVAC (the US brand of FSME-IMMUN, FDA-approved in 2021 for ages 1+) gives over 95% protection after three doses. Two doses a month apart already cover most of a single travel season.
- TBE does not spread person to person. The only non-tick route is unpasteurized goat, sheep, or cow milk and cheese from infected herds.
- There is no specific antiviral. Treatment is supportive, and 10 to 20% of neurological-phase patients have lasting deficits.
What is tick-borne encephalitis?
TBE is a viral infection of the central nervous system caused by tick-borne encephalitis virus (TBEV), a flavivirus related to West Nile, Japanese encephalitis, and dengue. Infected Ixodes ticks transmit the virus during a blood meal, and it crosses into the brain in roughly a quarter of clinically apparent cases. The illness has two phases separated by a brief well period.
The first phase begins 7 to 14 days after the bite with fever, fatigue, headache, and muscle aches that look like influenza. Most patients recover here and never know they had TBE. About a quarter relapse after a symptom-free interval of 1 to 20 days into a neurological phase with high fever, severe headache, neck stiffness, confusion, or paralysis.
Severity tracks the viral subtype. European-subtype infections are most often a meningitis pattern with full recovery. Far Eastern-subtype infections are more often encephalitic, more often fatal, and more often leave lasting deficits. Children usually have milder courses than adults, and adults over 60 carry the highest risk of severe disease.
Where does TBE circulate?
TBE is endemic across a wide band of Europe and northern Asia, from northeastern France through central and eastern Europe to Russia, China, Mongolia, Korea, and northern Japan. ECDC reports the highest incidence in Austria, Czechia, Germany (especially Bavaria and Baden-Württemberg), Switzerland, Slovenia, Slovakia, Poland, the Baltics, and Russia. Sweden, Finland, the Netherlands, and the UK have all reported autochthonous cases in the past decade where the virus was previously absent.
The three viral subtypes split roughly along longitude. The table below summarizes the geographic and clinical differences and where licensed vaccines provide protection.
| Subtype | Geography | Severity | Vaccine coverage |
|---|---|---|---|
| European | Western, central, and northern Europe | Mortality 1 to 2%; mostly meningitis pattern | Yes (TICOVAC, FSME-IMMUN, Encepur) |
| Siberian | Russia, Baltic states, Finland, parts of central Asia | Mortality 2 to 3%; chronic forms occasionally reported | Cross-protection from European-strain vaccines |
| Far Eastern | Russian Far East, China, northern Japan, Korea | Mortality up to 20%; encephalitic pattern with high disability | Cross-protection from European-strain vaccines; Russian EnceVir is matched to local strain |
Climate change has pushed the active range upward in altitude and latitude. Norwegian and Scottish surveillance now picks up TBEV from places where it was undetectable in the early 2000s. ECDC's 2024 report flagged a clear northward trend, and several first-ever autochthonous cases were confirmed in the UK between 2019 and 2024.
How does TBE spread to humans?
TBE spreads through the bite of an infected Ixodes tick, almost always I. ricinus in Europe or I. persulcatus in eastern Europe and Asia. Unlike Lyme, where the bacterium needs 36 to 48 hours of attachment to transmit, TBEV passes from the tick's salivary glands within minutes to hours. Quick removal helps but is not as protective as for Lyme.
A second route exists: unpasteurized milk and fresh cheese from infected goats, sheep, or cows. Small alimentary outbreaks are documented in Slovakia, Hungary, Austria, and the Baltics. Pasteurization inactivates the virus, so commercial dairy is safe.
Tick activity peaks twice in temperate Europe: a primary peak from April through July and a secondary peak in September and October. Hikers, foragers, mountain bikers, campers, and forestry workers carry the highest risk. Walking paved paths in city parks is low-risk; stepping off-trail through grass or leaf litter in an endemic area is the tick's preferred hunting ground.
What are TBE symptoms and outcomes?
The first phase looks like a nonspecific viral illness: fever, headache, muscle aches, and fatigue 7 to 14 days after the bite. Roughly two thirds of patients clear the virus here. The remaining third develops neurological symptoms after a brief well period, including high fever, severe headache, neck stiffness, tremor, confusion, or weakness.
Three patterns dominate the neurological phase. Meningitis (about 50%) presents with stiff neck, headache, and fever and usually resolves fully. Meningoencephalitis (about 40%) adds confusion, behavior change, tremor, and sometimes seizures. Meningoencephalomyelitis (about 10%) involves the spinal cord with limb paralysis, and recovery is often incomplete.
ECDC and Austrian data put lasting neurological deficits in 10 to 20% of neurological-phase patients a year out, including cognitive slowing, hearing loss, persistent fatigue, and partial paralysis. Mortality runs 1 to 2% for European-subtype disease and rises sharply with age.
Who should consider the TBE vaccine?
CDC and ACIP recommend the TBE vaccine (TICOVAC) for travelers whose itinerary includes substantial outdoor exposure (hiking, camping, foraging, forestry, fieldwork, military training) in endemic areas during the April-to-November tick season. Short-stay urban travelers generally do not need it. The decision rests on the kind of exposure, not the country alone.
The primary series is three doses on a 0, 1 to 3 month, and 5 to 12 month schedule. Two doses one month apart already give over 90% seroconversion and cover most of a single travel season, which is the practical regimen for most US travelers planning a summer trip. An accelerated schedule (0, 14 days) is approved for last-minute travelers. A booster is recommended every 3 to 5 years for ongoing exposure.
TICOVAC has been sold in Europe as FSME-IMMUN since the 1970s, and Austria's high-uptake program has cut national TBE incidence by an estimated 90%. Travel clinic stocking is the binding US constraint, not vaccine availability. The travel vaccinations timing guide covers how TBE fits into the pre-departure schedule.
How do you reduce tick exposure during European travel?
Wear long pants tucked into socks, treat outer clothing with permethrin (kills ticks on contact, lasts through several wash cycles), use 20 to 30% DEET or picaridin on skin, walk in the center of trails, do a full-body tick check at the end of every day outdoors, and shower within 2 hours of coming in. The same stack covers TBE, Lyme, anaplasmosis, and most other Ixodes-borne pathogens.
Common adult attachment sites are groin, waistband, armpits, behind the knees, scalp, and back of the neck. For children, the head, neck, and ears are highest-yield. Nymph ticks the size of a poppy seed cause most human TBE infections and are easy to miss without a deliberate check.
If you find an attached tick, use fine-tipped tweezers to grasp it close to the skin and pull straight up with steady pressure. Skip the folk remedies (matches, nail polish, petroleum jelly), which delay removal and can make the tick regurgitate into the bite. There is no post-exposure prophylaxis for TBE the way doxycycline works for Lyme, so a tick removed early still warrants 30 days of self-monitoring for fever or neurological symptoms. Skip unpasteurized dairy from farm-direct sources in endemic regions during tick season.
FAQ
Is the TBE vaccine available in the US?
Yes. FDA approved TICOVAC (Pfizer) for ages 1 and up in August 2021. It is the same vaccine sold in Europe as FSME-IMMUN. Stocking is uneven across US travel clinics because demand has been low, and many primary care practices do not carry it at all. Calling ahead to a dedicated travel medicine clinic is the most reliable way to get the vaccine before a European trip.
Do I need TBE vaccination for a city trip to Berlin or Vienna?
Probably not. CDC reserves TBE vaccination for itineraries with meaningful outdoor exposure (hiking, camping, fieldwork, forestry, foraging, military deployments) in endemic regions during active tick season. A short urban trip with day excursions on paved paths is a low-yield use of the vaccine. A two-week summer hike through Bavaria or the Baltics is exactly what it is for.
Can you get both TBE and Lyme from one tick bite?
Yes. European I. ricinus ticks carry Borrelia burgdorferi sensu lato (Lyme), TBEV, Anaplasma, and several other pathogens. Co-infection is documented in case series from central and eastern Europe. A single bite can start both diseases on independent timelines, which is why post-bite monitoring should cover the full 30-day window for any tick-borne illness.
How long does TBE vaccine protection last?
The three-dose primary series gives over 95% protection for at least 3 years per ECDC and Austrian surveillance. CDC and the European product label recommend a booster every 3 to 5 years for ongoing exposure, with the longer interval for adults under 60 and the shorter interval for older adults whose antibody titers fall faster.